Single-institution database launched to evaluate Carbetocin outcomes in all cesarean deliveries

Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality. Uterotonic agents are crucial for preventing PPH by promoting uterine contraction. Oxytocin is the standard, but its short half-life often necessitates additional agents. Carbetocin, a long-acting oxytocin analog, has shown promise in reducing the need for secondary uterotonics, yet its adoption for cesarean delivery (CD) is inconsistent across institutions despite some guidelines. This study aims to bridge the data gap on real-world outcomes.

Researchers initiated a prospective, single-institution database to collect electronic data on all cesarean deliveries (CDs), both elective and emergent, over a one-year period. The study evaluates the efficacy and clinical outcomes of using Carbetocin as the first-line uterotonic for all CDs. Data on additional uterotonic use and impact on intra- and postoperative outcomes are gathered using a Microsoft Dynamics CRM database accessible via smart devices. The primary outcome is the rate of additional uterotonic use compared to literature benchmarks for oxytocin.

This research record describes the initiation of a prospective database to collect real-world data on Carbetocin use in cesarean deliveries. As a study protocol, it does not present specific numerical findings or outcomes. Data collection is ongoing for one year, focusing on the need for additional uterotonics and impact on intra- and postoperative outcomes. No efficacy or safety data are reported here. > The primary outcome of this database study is to evaluate the use of additional uterotonics in patients receiving Carbetocin compared to historical oxytocin data.